itolizumab-matching placebo, EQ001 clinical trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease

This study is testing a new medicine, itolizumab, for people who have complications after a stem cell transplant, called acute graft versus host disease (aGVHD). It compares itolizumab with a dummy medicine (placebo) to see if it helps more people get better.